A study on a novel glaucoma treatment technique, bio-scaffolded cyclodialysis (BSC), showed promising results in a case series involving 243 eyes, according to data published in the Journal of Clinical Medicine. The procedure improved IOP in 78.6% of cases without an increase in medication use. The study focused on patients with open-angle glaucoma, 79% of whom also underwent cataract surgery.

In the BSC approach, the microinvasive CycloPen system (Iantrek) is used to create a cyclodialysispathway between the anterior chamber and the suprachoroidal space. The device then places biocompatible allograft tissue (a bio-scaffold) to help keep the drainage pathway open, ensuring a controlled and stable flow of fluid.

The study found no sight-threatening complications. Minor issues, such as hyphema and prolonged iritis, were resolved through conservative management. Only 4.5% of cases experienced elevated IOP requiring secondary interventions. These results suggest that scleral allografts offer a biocompatible, long-lasting solution for enhancing uveoscleral outflow, potentially reducing the need for more invasive hardware implants, the study authors concluded, noting that further studies are needed to confirm long-term efficacy.